Morristown, N.J., USA - October 15, 2010, Morristown, N.J., USA - Durata Therapeutics, a biopharmaceutical company, announced the formation of the senior leadership team with the appointments of Paul R. Edick as CEO, Corey N. Fishman as COO and Michael Dunne as chief medical officer.
Article continues below
Mr. Edick has extensive experience bringing new therapeutics to market. Mr. Edick’s most recent position was as Chief Executive Officer of GANIC Pharmaceuticals, a Warburg Pincus investment vehicle. Prior to that, as CEO of MedPointe Healthcare Inc., he led significant growth of the commercial portfolio and development of a pipeline of clinical-stage assets.
Mr. Edick also led the negotiated sale of MedPointe in 3Q 2007 to Meda AB, Sweden. Prior to this, he held various senior executive positions at G.D. Searle and its acquirer, Pharmacia Corporation. During his tenure, he headed the Global Pain & Inflammation Business, responsible for the strategy and planning for the launch of Celebrex and he also led US marketing during the growth phase of Ambien.
Previously, Mr. Edick held sales management positions at Ortho Pharmaceuticals and general management positions at Hamilton Communications and Caremark. Mr. Edick is an independent director of several companies, and Chairman of Life Cycle Pharma, a public technology-based biotech in Copenhagen, Denmark. He received his BA degree from Hamilton College.
Mr. Fishman has more than 18 years of experience in the pharmaceutical industry leading a variety of functions including operations, finance, business development and strategy. Mr. Fishman has negotiated and closed over $1 billion of transactions in the pharmaceutical industry.
Mr. Fishman's most recent position was as Chief Financial Officer of GANIC Pharmaceuticals, a Warburg Pincus company. Before that, he was CFO of MedPointe Healthcare, where he led finance, manufacturing, supply chain, business development and portfolio optimization.
Previously, Mr. Fishman served in senior level finance positions in both private and public companies, where he raised over $50 million in the capital markets and executed multiple debt refinancings. He also led Monsanto Company’s global financial planning and analysis organization.
Mr. Fishman received his BA degree from the University of Illinois and his Masters in Management from the Krannert School of Management at Purdue University.
Mr. Dunne, MD, has more than 17 years of experience in the pharmaceutical industry. Most recently, Dr. Dunne was the Vice President and Therapeutic Area Head responsible for the clinical development of compounds in the Anti-Infective Franchise at Pfizer, Inc.
In that role Mr. Dunne was responsible for the development and successful registration of various anti-fungal, anti-bacterial and anti-viral products, including those for treatment of HIV infection. Included in that portfolio of compounds was dalbavancin, over which he had direct oversight.
Dr. Dunne is a member of the Infectious Diseases Society of America, the American Society of Microbiology, as well as the American College of Physicians. He received his BA degree in Economics at Northwestern University, and his MD degree at the State University of New York Health Sciences Center in Brooklyn. ■